Physician profile
Danielle E Stephens
NPI 1528200367
$2,974.64
in general payments reported to CMS, 2019-2025
29 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $593 · 2023: $694 · 2024: $718 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $359.09 | 2021-2025 | Freestyle Libre 3, Aveir, Amplatzer Amulet |
| Abbvie INC. | $349.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.87 | 2021-2024 | Stiolto Respimat |
| Glaxosmithkline, LLC. | $324.22 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $197.54 | 2021-2025 | |
| Amgen INC. | $177.64 | 2021-2024 | Otezla, Repatha, Evenity |
| Kowa Pharmaceuticals America, INC. | $165.62 | 2021-2022 | |
| Novo Nordisk INC | $126.34 | 2021-2024 | Wegovy |
| Dexcom, INC. | $124.36 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $114.81 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $98.94 | 2021-2023 | |
| Lilly USA, LLC | $95.31 | 2021-2023 | Mounjaro, Trulicity |
| Astellas Pharma US INC | $95.23 | 2021-2024 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $76.07 | 2022 | |
| Sumitomo Pharma America, INC. | $48.23 | 2023-2024 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.41 | 2021-2024 | |
| Boston Scientific Corporation | $37.06 | 2023-2024 | Watchman Flx |
| Ibsa Pharma INC. | $30.93 | 2022-2023 | Tirosint, Licart |
| Daiichi Sankyo INC. | $28.50 | 2023 | Injectafer |
| Exact Sciences Corporation | $19.47 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $16.76 | 2021 | |
| Lundbeck LLC | $15.60 | 2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $15.30 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.34 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.94 | 2021 | |
| Merck Sharp & Dohme LLC | $12.90 | 2023 | Belsomra |
| Currax Pharmaceuticals LLC | $12.78 | 2021 | |
| Corium, LLC | $10.88 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.